Advance Phase III Clinical Trial of the Drug Jusvinza for the Treatment of Rheumatoid Arthritis
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
The Cuban drug Jusvinza is currently undergoing a Phase III clinical trial, the results will depend on its definitive approval in the therapy of rheumatoid arthritis.
Facebook Twitter WhatsApp After receiving, in September 2023, the medical record conditioned for the treatment of rheumatoid arthritis (RA), the Cuban drug Jusvinza is currently undergoing a Phase III clinical trial, which should be completed soon, and whose results will depend on its definitive approval in the therapy of this disease. Dr. María del Carmen Domínguez Horta, leader of this research project at the Center for Genetic Engineering and…
Havana, Jun 11 (RHC) After receiving, in September 2023, the medical record conditioned for the treatment of rheumatoid arthritis (RA), the Cuban drug Jusvinza is currently undergoing a Phase III clinical trial, which should be completed soon, and the results of which will depend on its definitive approval in the therapy of this disease.
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
